Cargando…
Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor
BACKGROUND: Oviedomycin is one among several polyketides known for their potential as anticancer agents. The biosynthetic gene cluster (BGC) for oviedomycin is primarily found in Streptomyces antibioticus. However, because this BGC is usually inactive under normal laboratory conditions, it is necess...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576301/ https://www.ncbi.nlm.nih.gov/pubmed/37838667 http://dx.doi.org/10.1186/s12934-023-02218-8 |
_version_ | 1785121091334701056 |
---|---|
author | Gu, Boncheol Kim, Duck Gyun Kim, Do-Kyung Kim, Minji Kim, Hyun Uk Oh, Min-Kyu |
author_facet | Gu, Boncheol Kim, Duck Gyun Kim, Do-Kyung Kim, Minji Kim, Hyun Uk Oh, Min-Kyu |
author_sort | Gu, Boncheol |
collection | PubMed |
description | BACKGROUND: Oviedomycin is one among several polyketides known for their potential as anticancer agents. The biosynthetic gene cluster (BGC) for oviedomycin is primarily found in Streptomyces antibioticus. However, because this BGC is usually inactive under normal laboratory conditions, it is necessary to employ systematic metabolic engineering methods, such as heterologous expression, refactoring of BGCs, and optimization of precursor biosynthesis, to allow efficient production of these compounds. RESULTS: Oviedomycin BGC was captured from the genome of Streptomyces antibioticus by a newly constructed plasmid, pCBA, and conjugated into the heterologous strain, S. coelicolor M1152. To increase the production of oviedomycin, clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system was utilized in an in vitro setting to refactor the native promoters within the ovm BGC. The target promoters of refactoring were selected based on examination of factors such as transcription levels and metabolite profiling. Furthermore, genome-scale metabolic simulation was applied to find overexpression targets that could enhance the biosynthesis of precursors or cofactors related to oviedomycin production. The combined approach led to a significant increase in oviedomycin production, reaching up to 670 mg/L, which is the highest titer reported to date. This demonstrates the potential of the approach undertaken in this study. CONCLUSIONS: The metabolic engineering approach used in this study led to the successful production of a valuable polyketide, oviedomycin, via BGC cloning, promoter refactoring, and gene manipulation of host metabolism aided by genome-scale metabolic simulation. This approach can be also useful for the efficient production of other secondary molecules encoded by ‘silent’ BGCs. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02218-8. |
format | Online Article Text |
id | pubmed-10576301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105763012023-10-15 Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor Gu, Boncheol Kim, Duck Gyun Kim, Do-Kyung Kim, Minji Kim, Hyun Uk Oh, Min-Kyu Microb Cell Fact Research BACKGROUND: Oviedomycin is one among several polyketides known for their potential as anticancer agents. The biosynthetic gene cluster (BGC) for oviedomycin is primarily found in Streptomyces antibioticus. However, because this BGC is usually inactive under normal laboratory conditions, it is necessary to employ systematic metabolic engineering methods, such as heterologous expression, refactoring of BGCs, and optimization of precursor biosynthesis, to allow efficient production of these compounds. RESULTS: Oviedomycin BGC was captured from the genome of Streptomyces antibioticus by a newly constructed plasmid, pCBA, and conjugated into the heterologous strain, S. coelicolor M1152. To increase the production of oviedomycin, clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system was utilized in an in vitro setting to refactor the native promoters within the ovm BGC. The target promoters of refactoring were selected based on examination of factors such as transcription levels and metabolite profiling. Furthermore, genome-scale metabolic simulation was applied to find overexpression targets that could enhance the biosynthesis of precursors or cofactors related to oviedomycin production. The combined approach led to a significant increase in oviedomycin production, reaching up to 670 mg/L, which is the highest titer reported to date. This demonstrates the potential of the approach undertaken in this study. CONCLUSIONS: The metabolic engineering approach used in this study led to the successful production of a valuable polyketide, oviedomycin, via BGC cloning, promoter refactoring, and gene manipulation of host metabolism aided by genome-scale metabolic simulation. This approach can be also useful for the efficient production of other secondary molecules encoded by ‘silent’ BGCs. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-023-02218-8. BioMed Central 2023-10-14 /pmc/articles/PMC10576301/ /pubmed/37838667 http://dx.doi.org/10.1186/s12934-023-02218-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Gu, Boncheol Kim, Duck Gyun Kim, Do-Kyung Kim, Minji Kim, Hyun Uk Oh, Min-Kyu Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor |
title | Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor |
title_full | Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor |
title_fullStr | Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor |
title_full_unstemmed | Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor |
title_short | Heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain Streptomyces coelicolor |
title_sort | heterologous overproduction of oviedomycin by refactoring biosynthetic gene cluster and metabolic engineering of host strain streptomyces coelicolor |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576301/ https://www.ncbi.nlm.nih.gov/pubmed/37838667 http://dx.doi.org/10.1186/s12934-023-02218-8 |
work_keys_str_mv | AT guboncheol heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor AT kimduckgyun heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor AT kimdokyung heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor AT kimminji heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor AT kimhyunuk heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor AT ohminkyu heterologousoverproductionofoviedomycinbyrefactoringbiosyntheticgeneclusterandmetabolicengineeringofhoststrainstreptomycescoelicolor |